U.S. markets open in 2 hours 14 minutes
  • S&P Futures

    3,448.50
    +25.75 (+0.75%)
     
  • Dow Futures

    28,306.00
    +206.00 (+0.73%)
     
  • Nasdaq Futures

    11,740.00
    +89.75 (+0.77%)
     
  • Russell 2000 Futures

    1,627.80
    +16.50 (+1.02%)
     
  • Crude Oil

    40.96
    +0.13 (+0.32%)
     
  • Gold

    1,908.60
    -3.10 (-0.16%)
     
  • Silver

    24.72
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1813
    +0.0040 (+0.34%)
     
  • 10-Yr Bond

    0.7610
    0.0000 (0.00%)
     
  • Vix

    28.37
    +0.96 (+3.50%)
     
  • GBP/USD

    1.2955
    +0.0014 (+0.11%)
     
  • USD/JPY

    105.5840
    +0.1540 (+0.15%)
     
  • BTC-USD

    11,903.84
    +846.83 (+7.66%)
     
  • CMC Crypto 200

    240.20
    +6.53 (+2.80%)
     
  • FTSE 100

    5,905.67
    +21.02 (+0.36%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference

·1 min read

CAMBRIDGE, Mass., May 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will participate in the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20 at 10:20 a.m. ET. A live webcast and replay of Akebia's presentation will be available on the Company's website at www.akebia.com.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-rbc-capital-markets-global-healthcare-virtual-conference-301055476.html

SOURCE Akebia Therapeutics